NCT05051436RecruitingPhase 4
The Effects of Mirabegron and Tadalafil on Glucose Tolerance in Prediabetics
Source: ClinicalTrials.gov · Last updated 31 Aug 2026
Brief summary (registry, in English)
The investigator hypothesizes that treatment with the ß3 agonist mirabegron results in improved glucose metabolism, including a reversal of prediabetes in obese, insulin-resistant human research participants, and this is further improved by combination therapy with tadalafil. The investigator will comprehensively analyze glucose homeostasis in prediabetic patients treated for 14 weeks with mirabegron, tadalafil or both drugs as compared to a placebo.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 96 (estimated)
- First submitted
- 10 Sept 2021
- Start date
- Dec 2021
- Primary completion date
- Jan 2027
- Lead sponsor
- Philip Kern
- Diseases
- Obesity
- NCT number
- NCT05051436
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 96
- From Dec 2021 to the primary completion date, Jan 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Chronic use of any antidiabetic medications
- Use of steroids or daily use of NSAIDS
Other illness
- Diabetes
- Any unstable medical condition
- History of chronic inflammatory conditions
- Any condition deemed risky by the study physician
Other
- Use of anticoagulants
- Contraindications to the use of mirabegron or tadalafil
Who the study is looking for
- Hemoglobin A1C between 5.7 and 6.4
- Body mass index between 27 and 45
Age in the registry: 35 years to 65 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Kentucky Coordinator of this site? Confirm its status | Lexington | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.